USPH Competitors
| USPH Stock | USD 85.58 1.51 1.80% |
US Physicalrapy vs Neogen Correlation
Poor diversification
The correlation between US Physicalrapy and NEOG is 0.73 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding US Physicalrapy and NEOG in the same portfolio, assuming nothing else is changed.
Moving together with USPH Stock
Moving against USPH Stock
| 0.7 | UHS | Universal Health Services | PairCorr |
| 0.66 | REG | Regis Healthcare | PairCorr |
| 0.54 | FLGT | Fulgent Genetics | PairCorr |
| 0.45 | S00 | Spire Healthcare | PairCorr |
| 0.42 | SPI | Spire Healthcare | PairCorr |
US Physicalrapy Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between US Physicalrapy and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of USPH and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of US Physicalrapy does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between USPH Stock performing well and US Physicalrapy Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze US Physicalrapy's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| HCSG | 1.33 | 0.06 | 0.02 | 0.15 | 2.19 | 3.74 | 13.01 | |||
| SEM | 1.14 | 0.16 | 0.15 | 0.21 | 0.82 | 2.25 | 13.50 | |||
| CNMD | 1.88 | (0.16) | 0.00 | (0.12) | 0.00 | 3.36 | 14.72 | |||
| AHCO | 1.98 | 0.26 | 0.08 | 1.03 | 2.10 | 4.59 | 24.44 | |||
| PNTG | 1.64 | 0.25 | 0.09 | 0.44 | 2.18 | 3.75 | 17.07 | |||
| GDRX | 1.98 | (0.56) | 0.00 | (0.29) | 0.00 | 3.33 | 10.97 | |||
| ZBIO | 5.55 | 0.08 | 0.00 | 0.02 | 0.00 | 9.05 | 68.95 | |||
| ASTH | 3.31 | (0.70) | 0.00 | (0.25) | 0.00 | 6.14 | 31.71 | |||
| KMTS | 2.47 | (0.08) | (0.02) | 0.01 | 3.86 | 4.59 | 20.54 | |||
| NEOG | 2.53 | 0.78 | 0.31 | 0.54 | 1.89 | 5.96 | 34.17 |
Cross Equities Net Income Analysis
Compare US Physicalrapy and related stocks such as Healthcare Services, Select Medical Holdings, and CONMED Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCSG | 1.5 M | 38.2 M | 44.2 M | 47.1 M | 21.9 M | 58 M | 77.4 M | 88.2 M | 83.5 M | 64.6 M | 98.7 M | 48.5 M | 34.2 M | 38.4 M | 39.5 M | 45.4 M | 29.1 M |
| SEM | (27.9 M) | 107.8 M | 148.2 M | 114.4 M | 120.6 M | 130.7 M | 115.4 M | 177.2 M | 137.8 M | 148.4 M | 259 M | 402.2 M | 159 M | 243.5 M | 214 M | 246.1 M | 151.6 M |
| CNMD | 700 K | 752 K | 40.5 M | 35.9 M | 32.2 M | 30.5 M | 14.7 M | 55.5 M | 40.9 M | 28.6 M | 9.5 M | 62.5 M | (80.6 M) | 64.5 M | 132.4 M | 47.1 M | 24.4 M |
| AHCO | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (690) | 2.1 M | (21.3 M) | (161.6 M) | 156.2 M | 69.3 M | (678.9 M) | 90.4 M | 81.4 M | 85.4 M |
| PNTG | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 9.9 M | 15.7 M | 2.5 M | 15.7 M | 2.7 M | 6.6 M | 13.4 M | 22.6 M | 25.9 M | 27.2 M |
| GDRX | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | 8.8 M | 43.8 M | 66 M | (293.6 M) | (25.3 M) | (32.8 M) | (8.9 M) | 16.4 M | 14.8 M | 15.5 M |
| ASTH | (5 K) | (720.3 K) | (8.9 M) | (5 M) | (1.8 M) | (9.3 M) | (9 M) | 25.8 M | 10.8 M | 14.1 M | (23.8 M) | 68.9 M | 45.2 M | 60.7 M | 43.1 M | 49.6 M | 52.1 M |
| KMTS | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (34.1 M) | (84.2 M) | (84.2 M) | (94.1 M) | (113.8 M) | (102.4 M) | (107.6 M) |
| NEOG | (1.1 M) | 22.5 M | 27.2 M | 28.2 M | 33.5 M | 36.6 M | 43.8 M | 63.1 M | 60.2 M | 59.5 M | 60.9 M | 48.3 M | (22.9 M) | (9.4 M) | (1.1 B) | (982.8 M) | (933.7 M) |
US Physicalrapy and related stocks such as Healthcare Services, Select Medical Holdings, and CONMED Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in US Physicalrapy financial statement analysis. It represents the amount of money remaining after all of US Physicalrapy operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.US Physicalrapy Competitive Analysis
The better you understand US Physicalrapy competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, US Physicalrapy's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across US Physicalrapy's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
US Physicalrapy Competition Performance Charts
Five steps to successful analysis of US Physicalrapy Competition
US Physicalrapy's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by US Physicalrapy in relation to its competition. US Physicalrapy's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of US Physicalrapy in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact US Physicalrapy's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to US Physicalrapy, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your US Physicalrapy position
In addition to having US Physicalrapy in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Exotic Funds Thematic Idea Now
Exotic Funds
Funds or Etfs with high minimum investment requirement that manage portfolios of alternative investments such as hedge funds, options, futures, real estate or commodities. The Exotic Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Exotic Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out US Physicalrapy Correlation with its peers. For more detail on how to invest in USPH Stock please use our How to Invest in US Physicalrapy guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is there potential for Health Care Providers & Services market expansion? Will USPH introduce new products? Factors like these will boost the valuation of US Physicalrapy. If investors know USPH will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about US Physicalrapy listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.236 | Dividend Share 1.79 | Earnings Share 2.37 | Revenue Per Share | Quarterly Revenue Growth 0.173 |
The market value of US Physicalrapy is measured differently than its book value, which is the value of USPH that is recorded on the company's balance sheet. Investors also form their own opinion of US Physicalrapy's value that differs from its market value or its book value, called intrinsic value, which is US Physicalrapy's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because US Physicalrapy's market value can be influenced by many factors that don't directly affect US Physicalrapy's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between US Physicalrapy's value and its price as these two are different measures arrived at by different means. Investors typically determine if US Physicalrapy is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, US Physicalrapy's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.